huCTLA-4-CHO-K is primarily used in immunological research and drug development, particularly in studies related to T-cell regulation and immune checkpoint pathways. It serves as a critical tool for investigating the mechanism of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a key inhibitory receptor on T cells that modulates early stages of immune responses. Due to its role in immune suppression, this molecule is employed in the development and testing of therapeutic antibodies targeting immune checkpoints, especially in oncology for cancer immunotherapy. It is also utilized in binding assays and functional studies to evaluate the efficacy and specificity of anti-CTLA-4 antibodies, such as those used in treatments for melanoma and other cancers. Additionally, it supports the production and validation of biologics in controlled expression systems, aiding in the assessment of protein stability, glycosylation patterns, and receptor-ligand interactions.